205 related articles for article (PubMed ID: 23579210)
1. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Boeck S; Wittwer C; Heinemann V; Haas M; Kern C; Stieber P; Nagel D; Holdenrieder S
Br J Cancer; 2013 Apr; 108(8):1684-94. PubMed ID: 23579210
[TBL] [Abstract][Full Text] [Related]
2. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.
Haas M; Kern C; Kruger S; Michl M; Modest DP; Giessen C; Schulz C; von Einem JC; Ormanns S; Laubender RP; Holdenrieder S; Heinemann V; Boeck S
Tumour Biol; 2015 Apr; 36(4):2631-40. PubMed ID: 25472579
[TBL] [Abstract][Full Text] [Related]
3. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
[TBL] [Abstract][Full Text] [Related]
4. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
5. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Kruger S; Heinemann V; Ross C; Diehl F; Nagel D; Ormanns S; Liebmann S; Prinz-Bravin I; Westphalen CB; Haas M; Jung A; Kirchner T; von Bergwelt-Baildon M; Boeck S; Holdenrieder S
Ann Oncol; 2018 Dec; 29(12):2348-2355. PubMed ID: 30346475
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
[TBL] [Abstract][Full Text] [Related]
10. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
11. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
12. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Heinemann V; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler TC; von Weikersthal LF; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Rubanov O; Baake G; Höhler T; Ko YD; Jung A; Neugebauer S; Boeck S
Gut; 2013 May; 62(5):751-9. PubMed ID: 22773551
[TBL] [Abstract][Full Text] [Related]
14. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
15. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
16. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.
Sato Y; Fujimoto D; Uehara K; Shimizu R; Ito J; Kogo M; Teraoka S; Kato R; Nagata K; Nakagawa A; Otsuka K; Hamakawa H; Takahashi Y; Imai Y; Tomii K
BMC Cancer; 2016 Nov; 16(1):890. PubMed ID: 27842505
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Chen F; Luo X; Zhang J; Lu Y; Luo R
Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
